however, had a significantly higher overall score for severity of illness at the start of treatment. More rapid drop of the clinical score was observed in the INF-a-2a group after treatment in the first three days and the two groups had similar clinical severity by day 3. There was no significant difference of the duration ofviral shedding in the two groups. In conclusion, the overall clinical improvement was greater in the treatment group over the first three days, but the duration of viral shedding was not altered.
Samples of blood were obtained on admission and before discharge to monitor the complete blood count and hepatic transaminases.
Comparability between the INF-a-2a and placebo treated groups was assessed using the Wilcoxon rank sum test and Fisher's exact test. The outcome measures including the duration of oxygen treatment, change in severity score between admission and day 1, day 2, day 3 and changes in temperature, heart rate, and respiratory rate were also compared by the Wilcoxon rank sum test. fig 1) . There were no significant differences in the changes of temperature, respiratory rate, and pulse rate between the two groups. The initial determination of the Sao2 showed that eight infants of the INF-a-2a treated group and 14 infants of the placebo 
